Flag of the European Union EU Clinical Trials Register Help

Clinical trials for C value

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44354   clinical trials with a EudraCT protocol, of which   7381   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,000 result(s) found for: C value. Displaying page 146 of 150.
    «« First « Previous 142  143  144  145  146  147  148  149  150  Next»
    EudraCT Number: 2008-005575-96 Sponsor Protocol Number: LPL100601 Start Date*: 2008-11-26
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
    Medical condition: chronic Coronary Heart Disease (cCHD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) HU (Completed) SE (Completed) DE (Completed) GB (Completed) SK (Completed) FR (Completed) DK (Completed) EE (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001778-21 Sponsor Protocol Number: A4001028 Start Date*: 2005-02-02
    Sponsor Name:PFIZER LTD
    Full Title: A multicentre, randomised, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimised background therapy versus optimised background therapy alone f...
    Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003346-17 Sponsor Protocol Number: M17OVH Start Date*: 2019-04-18
    Sponsor Name:NKI-AVL
    Full Title: Phase III Randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: OVHIPEC-2
    Medical condition: stage III epithelial ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004844-20 Sponsor Protocol Number: ADXS001-02 Start Date*: 2017-05-08
    Sponsor Name:Advaxis, Inc
    Full Title: Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence)
    Medical condition: High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent chemotherapy and radiation therapy.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10008231 Cervical cancer recurrent LLT
    19.1 100000004864 10008229 Cervical cancer LLT
    19.1 100000004864 10008236 Cervical cancer stage IV LLT
    19.1 100000004864 10008235 Cervical cancer stage III LLT
    19.1 100000004864 10008234 Cervical cancer stage II LLT
    19.1 100000004864 10008233 Cervical cancer stage I LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001699-20 Sponsor Protocol Number: 042011 Start Date*: 2012-05-18
    Sponsor Name:St. Anna Kinderkrebsforschung, GmbH
    Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS
    Medical condition: Langerhans cell histiocytosis
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001936-11 Sponsor Protocol Number: 3074K4-3339-WW Start Date*: 2009-03-20
    Sponsor Name:Wyeth Pharmaceuticals Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Clindamycin for the Treatment of Complicated Skin and Skin Structure Infections, Inc...
    Medical condition: Complicated skin and skin structure infection (cSSSI) with or without methicillin-resistant Staphylococcus aureus (MRSA)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040872 Skin infection LLT
    9.1 10066409 Staphylococcal skin infection LLT
    9.1 10066412 Staphylococcal aureus skin infection LLT
    9.1 10040872 Skin infection LLT
    9.1 10066409 Staphylococcal skin infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2013-003771-35 Sponsor Protocol Number: UX007G-CL201 Start Date*: 2014-02-11
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10039911 Seizures (incl subtypes) HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) FR (Ongoing) HU (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004302-18 Sponsor Protocol Number: GLPG1205-CL-220 Start Date*: 2018-06-18
    Sponsor Name:Galapagos NV
    Full Title: A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis.
    Medical condition: Idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) FR (Completed) BG (Completed) FI (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-001695-38 Sponsor Protocol Number: D1050301 Start Date*: 2014-03-11
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10001064 Acute schizophrenia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) IT (Not Authorised) Outside EU/EEA BG (Completed) HU (Completed) GB (Completed) BE (Completed) FR (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-014455-68 Sponsor Protocol Number: HOVON103AMLTosedostat Start Date*: 2010-08-16
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and ...
    Medical condition: patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 1...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037803 RAEB LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020387-38 Sponsor Protocol Number: AI452-005 Start Date*: 2010-12-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: LIRA-B - Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus...
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    16.0 10022891 - Investigations 10052329 Hepatitis B e antigen positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020185-19 Sponsor Protocol Number: KP7242114 Start Date*: 2011-05-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Optimization of Treatment and Management of Schizophrenia in Europe
    Medical condition: Schizophrenia ICD-10 code F20 or schizophreniform disorder ICD-10 code F23.1
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10039647 Schizophreniform disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) DK (Prematurely Ended) AT (Completed) BE (Completed) IT (Completed) BG (Completed) RO (Suspended by CA)
    Trial results: View results
    EudraCT Number: 2014-004842-92 Sponsor Protocol Number: SECOMBIT Start Date*: 2016-06-30
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit...
    Medical condition: Metastatic melanoma and BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) DE (Completed) GR (Completed) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007661-24 Sponsor Protocol Number: GLP112754 Start Date*: 2009-07-01
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: Estudio multicéntrico, aleatorizado, abierto y de grupos paralelos para determinar la eficacia y la seguridad a largo plazo de la albiglutida en comparación con la insulina en sujetos con diabetes ...
    Medical condition: Diabetes mellitus de tipo 2 Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007662-37 Sponsor Protocol Number: GLP112755 Start Date*: 2009-07-01
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para determinar la eficacia y la seguridad de la albiglutida administrada en combinación con pioglitaz...
    Medical condition: Diabetes mellitus de tipo 2 Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019690-15 Sponsor Protocol Number: GLP114179 Start Date*: 2010-07-27
    Sponsor Name:GlaxoSmithKline LLC
    Full Title: Estudio multicéntrico, aleatorizado, abierto y de grupos paralelos para determinar la eficacia y la seguridad de albiglutida en comparación con liraglutida en pacientes con diabetes mellitus de tip...
    Medical condition: Diabetes mellitus de tipo 2. Type 2 Diabetes Mellitus.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002714-72 Sponsor Protocol Number: GBG89 Start Date*: 2016-03-08
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4736 to a taxane-anthracycline containing chemotherapy in triple negative breast cancer. (GeparNuevo)
    Medical condition: Patients with triple negative, early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071115 Node-negative breast cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002840-21 Sponsor Protocol Number: HGT-GCB-039 Start Date*: 2007-10-30
    Sponsor Name:Shire Human Genetic Therapies Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared with Imiglucerase in Patients with Type I Gauc...
    Medical condition: Type I Gaucher disease Enfermedad de Gaucher tipo 1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018048 Gaucher's disease LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004299-38 Sponsor Protocol Number: ESPAC-4Version:7Date:21/07/2011 Start Date*: 2008-09-17
    Sponsor Name:The University of Liverpool [...]
    1. The University of Liverpool
    2. The Royal Liverpool and Broadgreen University Hospital NHS Trust
    Full Title: European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers.
    Medical condition: Resectable pancreatic or peri-ampullary cancers
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    14.1 100000004864 10034446 Periampullary carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Restarted) FI (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003415-26 Sponsor Protocol Number: 2021-003415-26 Start Date*: 2022-01-07
    Sponsor Name:Department of Oncology, Rigshospitalet
    Full Title: HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first line treatment for HER2 positive esophageal squamous cell carcinoma patients
    Medical condition: HER2 positive Esophageal Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041824 Squamous cell carcinoma of esophagus LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041825 Squamous cell carcinoma of esophagus NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056104 Squamous cell carcinoma of oesophagus LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 142  143  144  145  146  147  148  149  150  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Aug 15 21:08:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA